<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555785</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02106</org_study_id>
    <nct_id>NCT04555785</nct_id>
  </id_info>
  <brief_title>Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor</brief_title>
  <acronym>Will-Plate</acronym>
  <official_title>Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of high-normal dosage of Wilate ® compared to placebo administered in combination&#xD;
      with platelets to assess reduction of amount of blood loss, need of transfusion products and&#xD;
      outcome (length of stay, mortality) in patients with bleeding in comparison.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Von Willebrand Factor (vWF) is a key protein mediating platelet adhesion on the surface of&#xD;
      damaged endothelia, initiating platelet-platelet aggregation and supporting platelet&#xD;
      activation. It plays also an important role in protecting FVIII from early activation and&#xD;
      clearance . The product's included coagulation factor VIII acts in in the activated form like&#xD;
      the regular factor VIIIa. It takes part in the coagulation amplification by activating factor&#xD;
      X to Xa together with factor IVa. Activation of factor X results in generating thrombin out&#xD;
      of prothrombin. Wilate® is approved in Switzerland for prophylaxis and treatment of bleeding&#xD;
      in patients suffering from von Willebrand disease and Haemophilia A.&#xD;
&#xD;
      VWF is produced by the endothelial cells as a heterogeneous mixture of low and high molecular&#xD;
      weight units. VWF is a ligand for receptors on the platelet surface and endothelial cells&#xD;
      (GP1b-V-IX, αIIbβ3, αvβ3) mediating adhesion of platelets to each other or to the&#xD;
      endothelium. Initial platelet adhesion is a crucial step in haemostatic functioning. Loss of&#xD;
      platelets, vWF or blocking of these integrins due to the wide use of platelet aggregation&#xD;
      inhibitors can cause bleeding. In case of severe blood loss, these conditions often result in&#xD;
      mass transfusion.&#xD;
&#xD;
      There is suggestive evidence from an in-vitro flow chamber model and from treatment of&#xD;
      patients with severe vWF deficiency that increasing the concentration of vWF onto normal or&#xD;
      high normal levels can enhance platelet adhesion independent from platelet count. This might&#xD;
      translate into a better haemostatic effect of administered platelet concentrates in the&#xD;
      bleeding patient and less need for transfusion of blood products (platelet concentrates),&#xD;
      especially in clinical conditions with a high probability of low platelet count and low vWF&#xD;
      activities (e.g., heart surgery with extracorporeal circulation, ECMO).&#xD;
&#xD;
      To the best of our knowledge, no trial exists that investigated the effect of platelet&#xD;
      transfusion in combination with the administration of balanced vWF in severe blood loss. The&#xD;
      investigators hypothesize that simultaneous transfusion of platelets and balanced (1:1 vWF&#xD;
      and FVIII) vWF compared to placebo reduces the overall need of transfusion of blood products.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of blood products</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of blood products (platelets, fresh frozen plasma (FFP), red blood cells (RBC))</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Platelet transfusion with Wilate ®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Platelet transfusion with Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Wilate</intervention_name>
    <description>Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.</description>
    <arm_group_label>Platelet transfusion with Wilate ®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Empty placebo will be given with platelets in cases of severe bleeding.</description>
    <arm_group_label>Platelet transfusion with Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Admission to intensive care unit&#xD;
&#xD;
          -  Patients needing platelet transfusion during or after surgery with or without prior&#xD;
             treatment with single or dual antiplatelet agents (ASS, Prasugrel, Clopidogrel,&#xD;
             Ticagrelor)&#xD;
&#xD;
          -  Consent by the patient or a family member in addition to the consent of an independent&#xD;
             ICU physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving Factor VIII concentrate before inclusion of the study (Haemate ®)&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Participation in another study with an investigational drug within the 30 days&#xD;
             preceding and during the present study&#xD;
&#xD;
          -  Overt Disseminated Intravascular Coagulation (DIC)&#xD;
&#xD;
          -  Heparin-induced Thrombocytopenia (HIT)&#xD;
&#xD;
          -  Thrombotic Thrombocytopenic Purpura (TTP) or Haemolytic uremic Syndrome (HUS)&#xD;
&#xD;
          -  Idiopathic thrombocytopenic purpura (ITP)&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Patients with known inherited thrombocytopathies&#xD;
&#xD;
          -  Patients with known von Willebrand disease or Haemophilia A&#xD;
&#xD;
          -  Patients with known hemato-oncological diseases&#xD;
&#xD;
          -  Previous enrolment into the current study&#xD;
&#xD;
          -  Contraindications to the class of drugs under study, e.g. known hypersensitivity or&#xD;
             allergy to class of drugs or the investigational product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Siegemund, Prof. Dr. MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Siegemund, Prof. Dr. MD</last_name>
    <phone>0041613286414</phone>
    <email>martin.siegemund@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Blum, med. pract.</last_name>
    <phone>0041796903886</phone>
    <email>andrea.blum@hotmail.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

